T-cell-based vaccination

OSE Immunotherapeutics leverages its expertise in the selection and optimization of small proteins called peptides (epitopes or neo-epitopes) to deliver a rationally designed combination of multiple peptides with beneficial therapeutic potential.

The Company uses knowledge and expertise generated from its Memopi ® epitope (neo-epitope) optimization technology a combination of antitumor neo-epitopes to increase the memory immune response of T lymphocytes against specific antigens.

To receive OSE Immunotherapeutics’ latest news